Navigation Links
GNS Healthcare Announces Collaboration With Bristol-Myers Squibb

CAMBRIDGE, Mass., Aug. 10, 2011 /PRNewswire/ -- GNS Healthcare, Inc., (GNS) the leading healthcare analytics company focused on enabling personalized medicine to improve human health, today announced that it has entered into a collaboration with Bristol-Myers Squibb Company (NYSE: BMY) focused on the discovery of novel disease biology and biomarkers in the area of immuno-inflammation.  Utilizing its supercomputer-driven REFS™ (reverse-engineering and forward-simulation) platform, GNS will use clinical and molecular information from a Bristol-Myers Squibb clinical trial to build computer models in a hypothesis-free, unbiased manner that will be simulated to identify key molecular mechanisms. Financial terms of the agreement were not disclosed.

Using patient data comprised of genetic information, gene expression levels, specific blood markers and clinical outcomes researchers will use REFS to construct a comprehensive inflammation disease model directly from the raw data.  The resulting disease model is intended to support virtual clinical trials that will simulate the clinical effect of inhibiting various drug targets and help predict novel molecular targets to combat immuno-inflammation that would be effective for specific types of patients.

“We are pleased to be working with Bristol-Myers Squibb to identify biomarkers in immuno-inflammation,” said Dr. Iya Khalil, Executive Vice President and co-founder of GNS Healthcare. “This is the first step in building a significantly advanced in silico research paradigm that may enable development of new therapies based directly on human data, and address the needs of patients with particular genetics and molecular phenotypes, ultimately enabling the optimization of individualized patient outcomes.” 

About REFS

REFS is comprised of integrated machine learning algorithms and software that extract “causal” relationships from complex, multi-dimensional data and enable the simulation of billions of “what if?” hypotheses to explore novel unseen conditions and predictions forward in time.  REFS is licensed to GNS Healthcare from parent company Via Science.

About GNS Healthcare

GNS Healthcare, a subsidiary of Via Science, is a healthcare analytics company that applies machine learning and simulation technology to optimize patient treatment in partnership with health insurance companies, pharmacy benefit managers, health care providers, and pharmaceutical and biotech companies. GNS Healthcare is the leading “big data” healthcare analytics firm between drug makers and drug buyers, matching treatments to patients to deliver on the promise of “smart” medicine.  For more information, visit

GNS Healthcare, Inc.
Thomas A. Neyarapally, 617-494-0492
SVP, Corporate Development

SOURCE GNS Healthcare, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. ViroPharma to Present at Three Upcoming Healthcare Conferences
4. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
5. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
6. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
7. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
8. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
9. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
10. Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5
11. Immtech to Present at The Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Post Your Comments:
(Date:11/26/2015)... 2015 ) ... "Radioimmunoassay Market by Type (Reagents & Kits, ... Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), ... report to their offering. --> ... of the "Radioimmunoassay Market by Type ...
(Date:11/25/2015)... 2015 ... "Global Brain Monitoring Devices Market 2015-2019" ... ) has announced the addition ... Market 2015-2019" report to their offering. ... ) has announced the addition of ...
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... ... Effective immediately, every single IguanaMed scrub style will be available at Target via ... “Buy One Scrub Set, Get the 2nd Scrub Set 50% Off” for a limited ... price. , IguanaMed’s mission is to outfit every healer around the world ...
(Date:11/28/2015)... , ... November 28, 2015 , ... Safe storage for ... of two inventors, one from Lakewood, New Jersey and the other from Bradley Beach, ... patent-pending PROTECTOR to save the expense of having to replace NuvaRings more often than ...
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is back again ... choose from, the possibilities are endless. Users have full control over angle of view, ... masking effects, users are sure to get heads to turn. , ProPanel: Pulse offers ...
(Date:11/27/2015)... ... 27, 2015 , ... According to an article published November 6th ... the University of British Columbia suggested that laws requiring bicyclists to wear helmets may ... part of the reason for the controversial conclusion is that, while helmets have certainly ...
(Date:11/27/2015)... , ... November 27, 2015 , ... A team of ... ways to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy ...
Breaking Medicine News(10 mins):